Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (September 2022)
16 slides from Genetic Signatures's investor presentation, September 2022
Slide 1: Investor Update
Investor Update September 2022
Slide 2: Disclaimer
Investor DOCUMENT Presentation TITLE Disclaimer SEPTEMBER September 2021 2022 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written materials/slides for a verbal presentation con
Slide 3: Investment highlights
Investment highlights Investor DOCUMENT Presentation SEPTEMBER TITLE September 2021 2022 Proprietary 3base® technology platform that provides a revolutionary approach for molecular diagnostics Dramatically simplifies multiple pathogen testing from a single sample (multiplexing) • More informative –
Slide 4: Company Snapshot
Investor DOCUMENT Presentation TITLE Company Snapshot SEPTEMBER September 2021 2022 Financial information Share price (2-Sep-22) A$0.95 Shares on issue 143.4m1 Market capitalisation A$136.2m Cash (30-Jun-22) A$36.9m Debt (30-Jun-22) Nil Enterprise value A$99.3m Top shareholders % Asia Union 26.2% (C
Slide 5: 3base® - a revolution in molecular diagnostics
3base® - a revolution in molecular diagnostics Investor DOCUMENT Presentation SEPTEMBER TITLE September 2021 2022 Molecular diagnostic tests are based on DNA/RNA sequences • DNA/RNA is unique to each organism. Molecular diagnostic tests are recognised as the ‘gold standard’ • Precisely targeted and
Slide 6: How 3base® simplifies molecular targets
Investor DOCUMENT Presentation TITLE How 3base® simplifies molecular targets SEPTEMBER September 2021 2022 G A T G G C G A C A Genetic Signatures 3base® technology converts all C T G A T G G T G A T A G A T G G T G A T A Molecular target becomes the same for G A T G G T G A C A all three test sequen
Slide 7: How 3base® tests are performed
Investor DOCUMENT Presentation TITLE How 3base® tests are performed SEPTEMBER September 2021 2022 Proprietary method - patented until 2031+ Benefits 1. Extraction and Conversion • natural 4 bases to 3base® Rapid High throughput Informative Sensitive Specific Low manual involvement 2. DNA Amplificati
Slide 8: 3base® simplifies Syndromic Testing – EasyScreen™ Kits
3base® simplifies Syndromic Testing – EasyScreen™ Kits Investor DOCUMENT Presentation TITLE SEPTEMBER September 2021 2022 Syndromic testing: simultaneously test for multiple pathogens that all can cause the same signs and symptoms • Respiratory infections: cough, runny nose, sore throat, headache, b
Slide 9: Robust pipeline with multiple products cleared for sale
Investor DOCUMENT Presentation TITLE Robust pipeline with multiple products cleared for sale SEPTEMBER September 2021 2022 DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA planned in progress (expect 2023) Converting to new protocol planned planned In development 9
Slide 10: Track record of continued, strong revenue growth
Investor DOCUMENT Presentation TITLE Track record of continued, strong revenue growth SEPTEMBER September 2021 2022 Sales Revenue (A$m) FY22 sales revenue of $35.4 million (+25% yoy, 93% 4yr CAGR) Growing contribution from international sales Other 35.4 • Leveraging experience in Australian market;
Slide 11: Profitable and funded for growth
Investor DOCUMENT Presentation TITLE Profitable and funded for growth SEPTEMBER September 2021 2022 A$'000s FY22 FY21 Sales revenue 35,421 28,284 Profitable, cash flow positive with accelerated sales growth Cost of materials & freight (11,989) (9,804) • Sales revenue up 25% yoy; Gross profit 23,432
Slide 12: Growth initiatives
Investor DOCUMENT Presentation TITLE Growth initiatives SEPTEMBER September 2021 2022 Leverage experience in Australian market to grow international sales • Europe – drive adoption of other 3base® products; • US – build 3base® franchise once Protozoan Detection Kit is cleared. Build and expand portf
Slide 13: Enteric Protozoan kit will provide entry to North America
Investor DOCUMENT Presentation TITLE Enteric Protozoan kit will provide entry to North America SEPTEMBER September 2021 2022 Enteric Protozoan Screening Kit • Completed recruitment for 1,500 subject clinical trial; • Targeting 510(k) submission in Q4 CY2022; • First EasyScreen™ product for US High n
Slide 14: New products and instruments
Investor DOCUMENT Presentation TITLE New products and instruments SEPTEMBER September 2021 2022 Expand available EasyScreen™ Syndromic Kits • 3 kits research use only (RUO) – tropical diseases, MMR & meningitis; • Other kits in development (tick-borne, skin infections, etc.); • Advance additional 3
Slide 15: News flow and upcoming milestones – 12 months
News flow and upcoming milestones – 12 months Investor DOCUMENT Presentation SEPTEMBER TITLE September 2021 2022 US Enteric Protozoan Kit • File 510(k) application by end of CY2022; • Launch product once clearance is granted. Increase sales and presence in UK and European markets • Contracts with ne
Slide 16: Contact Us
Contact Us Dr John Melki Genetic Signatures Ltd Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Peter Manley Genetic Signatures Ltd Chief Financial Officer E: peter.manley@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 16
Genetic Signatures — Investor Presentation (September 2022) on 6ix